Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$19.56M+6987.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy T. Goodnow
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 130
- Beta
- 1.04
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.63
Financials
Revenue
$19.56M+6987.3%Net Income
$-32.68MEBITDA
$-32.04MFree Cash Flow
$-33.17MEPS (diluted)
$-0.50Shares Outstanding (diluted)
65.74M+1300.0%Operating Expenses
$43.92MCash & Debt
$126.30MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.26M | $-69.11M | $-1.66 |
| 2024 | $22.47M | $-78.62M | $-2.50 |
| 2023 | $22.39M | $-60.39M | $-2.20 |
| 2022 | $16.39M | $142.12M | $6.07 |
| 2021 | $13.68M | $-302.47M | $-14.40 |
| 2020 | $4.95M | $-175.17M | $-15.40 |
| 2019 | $21.30M | $-115.55M | $-12.20 |
| 2018 | $18.91M | $-93.97M | $-12.00 |
| 2017 | $6.37M | $-59.10M | $-10.20 |
| 2016 | $332.0K | $-43.93M | $-9.80 |
| 2015 | $38.0K | $-29.88M | $-6.60 |
| 2014 | $0.00 | $-18.89M | $-4.20 |
| 2013 | $17.0K | $-18.78M | $-5.00 |
Valuation
SENShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-16.67%Social Signal Score
Mentions (11)
- Newszacks.com·5d ago·Neutral
BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas Beta Bionics launches iLet Bionic Pancreas integration with Eversense 365, offering more CGM options and boosting growth prospects in the diabetes care market.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to reduce the demands of managing diabetes
View source ↗ - Newsmarketbeat.com·11d ago·Positive
Senseonics Holdings Sees $100 Million-Plus in 2027 Sales, Eyes New Eversense Launches Senseonics Holdings, Inc. Common Stock NASDAQ: SENS executives said the company's return of commercial operations in-house has improved efficiency and supported growth in its Eversense diabetes monitoring business, while outlining plans for new products and insulin pump partnerships.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·13d ago·Neutral
Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates Senseonics Holdings (SENS) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.43 per share a year ago.
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
What Senseonics Holdings, Inc. Common Stock (SENS) Said on Its Q3 Earnings Call Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported record third-quarter revenue and raised its 2026 sales outlook for the third time this year, as new patient starts for its Eversense 365 continuous glucose monitor drove growth in the United States and abroad.
View source ↗ - Newsglobenewswire.com·32d ago·Positive
…ings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.
View source ↗ - Newsseekingalpha.com·45d ago·Neutral
…he Valuation Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow pe…
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics' Eversense® 365 IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system.
View source ↗ - Newsglobenewswire.com·69d ago·Positive
… Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.
View source ↗ - Newsglobenewswire.com·73d ago·Positive
Senseonics To Participate in Upcoming Institutional Investor Conferences GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.
View source ↗
Earnings
Mon, Mar 1(in 3 months)
Consensus estimate $-0.41 per share
Typical surprise -2.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.50 vs $-0.52beat
- Thu, Aug 6$-0.63 vs $-0.61miss
- Thu, May 7$-0.71 vs $-0.69miss
- Mon, Mar 2$-0.46 vs $-0.43miss
- Wed, Nov 5$-0.43 vs $-0.33miss
- Wed, Aug 6$-0.40 vs $-0.40beat
Estimates and results for SENS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SENS officers and directors.
- Bought
- $737k
- Sold
- —
8 trades
0 trades
- Roeder Douglas Abought
- Roeder Douglas Abought
- Roeder Douglas Abought
- Goodnow Timothy Tbought
- Steven Edelmanbought
- Roeder Douglas Abought
- Sullivan Frederick T.bought
- Goodnow Timothy Tbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SENS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
